Sixteen analysts set USD 5.96 target for Evolent Health stock
Published on 10/15/2026 at 21:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and market measures
- MarketBeat's October 7, 2026 report put the average target at USD 5.96.
- Evolent Health will release third-quarter results on November 5, 2026.
- Evolent Health stock costs EUR 4.27 at Lang & Schwarz on October 15, 2026 at 9:16 p.m. CEST.
- Evolent Health had a market capitalization of USD 539.3 million on October 15, 2026.
Sixteen analysts assigned Evolent Health a Moderate Buy consensus and a USD 5.96 average 12-month target on October 7, 2026, according to MarketBeat. At the NYSE, the stock was last at USD 4.79 at 3:23 p.m. ET on October 15, 2026, putting the target 24.43 percent above that price. At Lang & Schwarz, Evolent Health stock was trading at EUR 4.27 on October 15, 2026 at 9:16 p.m. CEST.
November results have a date
Evolent Health will release its third-quarter 2026 financial results before the market opens on November 5, 2026. The company will hold a conference call at 8:30 a.m. ET, according to StockTitan. That date gives the next clear event on the calendar after the August 6, 2026 second-quarter report.
Price position and trading volume
The NYSE quote put Evolent Health's 52-week range at USD 2.10 to USD 8.30 as of October 15, 2026. The USD 4.79 price stood 42.29 percent below the high, leaving the stock well inside its yearly band. Trading volume reached 2,399,978 shares, versus an average of 2,985,037 shares, or 19.60 percent below the average.
On October 8, 2026, an earlier market report cited the same USD 5.96 consensus target and 16 analysts. The more useful question now is timing: the November 5 release will test whether the company can support the expectations embedded in that target.
Valuation and upcoming calendar
Evolent Health had a market capitalization of USD 539.3 million and a trailing P/E of minus 1.07 as of October 15, 2026. The company paid no dividend yield in the quoted period. Its healthcare services and technology model serves health plans and providers, with operations spanning administrative, clinical and analytical services.
Comparison with peers
Evolent Health (NYSE, USD): P/E minus 1.07, market capitalization USD 539.3 million
Privia Health (Nasdaq, USD): plus 4.57 percent, P/E 104.38, market capitalization USD 2.9 billion
Option Care Health (Nasdaq, USD): plus 0.24 percent, P/E 23.45, market capitalization USD 4.7 billion
Evolent Health stock at Lang & Schwarz
The euro quotation stood at EUR 4.27 at Lang & Schwarz on October 15, 2026 at 9:16 p.m. CEST. The NYSE quotation was USD 4.79 at 3:23 p.m. ET on the same date, keeping the two venue views separate. The further course of trading is shown by the continuously updated real-time quote of Evolent Health stock.
Evolent Health market facts
- Company: Evolent Health, Inc.
- ISIN: US30050B1017
- Ticker: EVH
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 15, 2026, 9:16 p.m. CEST): EUR 4.27
- Market capitalization: USD 539.3 million (as of October 15, 2026)
- 52-week range: USD 2.10-8.30 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical - Healthcare Information Services
Market context: Market report S&P 500.
